Lu, J., Hu, D., Zhang, Y., Ma, C., Shen, L., & Shuai, B. (2023). Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Frontiers in Oncology, 13, . https://doi.org/10.3389/fonc.2023.1133828
Chicago-referens (17:e uppl.)Lu, Junjie, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen, och Bo Shuai. "Current Comprehensive Understanding of Denosumab (the RANKL Neutralizing Antibody) in the Treatment of Bone Metastasis of Malignant Tumors, Including Pharmacological Mechanism and Clinical Trials." Frontiers in Oncology 13 (2023). https://doi.org/10.3389/fonc.2023.1133828.
MLA-referens (9:e uppl.)Lu, Junjie, et al. "Current Comprehensive Understanding of Denosumab (the RANKL Neutralizing Antibody) in the Treatment of Bone Metastasis of Malignant Tumors, Including Pharmacological Mechanism and Clinical Trials." Frontiers in Oncology, vol. 13, 2023, https://doi.org/10.3389/fonc.2023.1133828.
